Kimberly Schultheiss is a pharmacist who is specialized in Oncology in Fruitland, Idaho. Patients can reach her at 1118 Nw 16th St Ste D, Fruitland or contact her on 205-452-8698. Active license number of Kimberly Schultheiss is P5539 for Oncology in Idaho. Kimberly Schultheiss is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Kimberly Schultheiss speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Kimberly Schultheiss
Specialization:
Oncology
Credentials:
RPH
Gender:
Female
Location:
1118 Nw 16th St Ste D, Fruitland, Idaho, 83619-2272
Phone:
205-452-8698
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Kimberly Schultheiss are as mentioned below.
NPI Number:
1619515863
NPI Enumeration Date:
18 Dec, 2019
NPI Last Update On:
18 Dec, 2019
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Kimberly Schultheiss are as mentioned below.
Specialization
License Number
State
Status
Oncology
P5539
Idaho
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1118 Nw 16th St Ste D, Fruitland, Idaho
Zip:
83619-2272
Phone Number:
205-452-8698
Fax Number:
--
Patients can reach Kimberly Schultheiss at 1118 Nw 16th St Ste D, Fruitland, Idaho or can call on phone at 205-452-8698.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.